Patient info Open main menu

NATURES GARDEN LEMON BALM CAPSULES,HOLLAND & BARRETT LEMON BALM CAPSULES,GNC LIVE WELL LEMON BALM CAPSULES,LIFECYCLE LEMON BALM CAPSULES,NATURES BOUNTY LEMON BALM CAPSULES - summary of medicine characteristics

Dostupné balení:

Summary of medicine characteristics - NATURES GARDEN LEMON BALM CAPSULES,HOLLAND & BARRETT LEMON BALM CAPSULES,GNC LIVE WELL LEMON BALM CAPSULES,LIFECYCLE LEMON BALM CAPSULES,NATURES BOUNTY LEMON BALM CAPSULES

SUMMARY OF PRODUCT CHARACTERISTICS1 NAME OF THE MEDICINAL PRODUCT

Holland & Barrett Lemon Balm Capsules

Lifecycle Lemon Balm Capsules

GNC Live Well Lemon Balm Capsules

Nature's Garden Lemon Balm Capsules

Nature's Bounty Lemon Balm Capsules

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each capsule contains 171mg of extract (as dry extract) from Lemon Balm leaf (Melissa officinalis L.) (equivalent to 684mg – 1026mg of Lemon Balm leaf). Extraction solvent: Ethanol 50% v/v.

3 PHARMACEUTICAL FORM

Capsule, hard

Two piece clear hard capsules with green brown powder fill

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

A traditional herbal medicinal product used for the temporary relief of symptoms of mild anxiety, to aid sleep and for mild digestive complaints, such as bloating and flatulence, based on traditional use only.

4.2 Posology and method of administration

For oral use only

Adults and elderly:

Take 2 capsule 3 times daily.

Swallow the whole capsule with water.

The use in children or adolescents under 18 years is not recommended (see section 4.4 ‚Special Warnings and Precautions for use‘).

Duration of use:

If symptoms worsen or persist after 2 weeks during the use of this medicinal product, a doctor or a qualified healthcare practitioner should be consulted.

4.3 Contraindications

Hypersensitivity to Lemon Balm or any of the excipients

4.4 Special warnings and precautions for use

Do not exceed stated dose.

The use in children and adolescents under 18 years of age is not recommended because data are not sufficient and medical advice should be sought.

If symptoms worsen or persist after 2 weeks during the use of this medicinal product, a doctor or a qualified healthcare practitioner should be consulted.

4.5 Interaction with other medicinal products and other forms of interaction No data is available.

Although no clinical data about interactions with synthetic sedatives are available, concomitant use with synthetic sedatives (such as benzodiazepines) is not recommended unless advised by a doctor.

4.6 Fertility, pregnancy and lactation

Safety during pregnancy and lactation has not been established. In the absence of sufficient data, use during pregnancy and lactation is not recommended.

No studies on the effects on fertility have been performed.

4.7 Effects on ability to drive and use machines

May impair the ability to drive and use machines. Affected patients should not drive or operate machinery.

4.8 Undesirable effects

None known.

If adverse reactions occur, a doctor or a qualified healthcare practitioner should be consulted.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme website at: www.mhra.gov.uk/yellowcard.

4.9 Overdose

4.9 Overdose

No case of overdose has been reported.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Not required as per Article 16c(I)(a)(iii) of Directive 2001/83/EC amended.

5.2 Pharmacokinetic properties

Not required as per Article 16c(I)(a)(iii) of Directive 2001/83/EC amended.

5.3 Preclinical safety data

5.3 Preclinical safety data

Reverse mutation assays (Ames test) on bacteria indicated that the extract in product was not mutagenic in Salmonella typhimurium (strains TA 98, TA 100, TA 102, TA 1535 and TA 1537) mutation assays with or without metabolic activation.

Tests on reproductive toxicity and carcinogenicity have not been performed.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Calcium hydrogen phosphate dihydrate

Magnesium stearate, Silica colloidal hydrated

Excipients in the extract:

Maltodextrin

Silica colloidal anhydrous

Capsule shell:

Hypromellose

6.2 Incompatibilities

Not applicable

6.3 Shelf life

Three years

6.4 Special precautions for storage

Store below 25°C

Keep the bottle tightly closed

Store in the original container

6.5 Nature and contents of container

Container:

Green Polyethylene terephthalate (PET) bottles with a green flip cap (polypropylene), with an inner seal liner designed to lift ‚n‘ peel. The inner seal acts as a tamper evident seal under the cap. The inner seal liner is made up of polyester film, polymer adhesive layer, polyester tab, polyolefin foam, aluminium foil and sealable polyester film.

Pack size: 30 capsules

6.6 Special precautions for disposal

6.6 Special precautions for disposal

No special requirements

7 MARKETING AUTHORISATION HOLDER

Holland & Barrett International Limited

Samuel Ryder House,

Barling Way,

Nuneaton,

Warwickshire

CV10 7RH

United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

THR 21710/0004

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THEAUTHORISATION

21/02/2020